The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
Brazil: Anvisa Defends Newly-won Right to Deny Patents
Posted 12 July 2012 | By
Brazilian regulatory authorities are looking to keep newly-won authority to deny the grant of patents for medical products-authority won in 2012 as the result of patent reforms.
Speaking at a 10 July 2012 hearing before the Brazilian House of Representatives, Anvisa's Coordinator for Intellectual Property, Antonio Carlos Bezerra, told legislators that the agency ensures that there is no "undue delay in the arrival of competitors."
"An estimated $28 billion economy for the population under the introduction of generics into the market," added Bezerra.
The House is currently considering Bill 3.709/2008, which would remove Anvisa's veto authority by ending their participation in the evaluation of patents entirely.
The issue of access to drugs is particularly prescient in Brazil, where citizens are guaranteed the ability to have universal access to medicines by their constitution. A statement by Anvisa said taking away their pre-review authority would "[carry] risks for the public health model of the country."
Anivsa - Debate on prior informed consent brings together experts in the House
Regulatory Focus - Brazil: Regulatory Agency Gets Authority to Deny Patents
Get more Breaking News from RegLink